SEHK:2171Biotechs
CARsgen Therapeutics Holdings SEHK 2171 Valuation After Stronger 2025 Results And Narrowed Net Loss
CARsgen Therapeutics Holdings (SEHK:2171) has drawn attention after reporting full year 2025 earnings, with sales of CNY 125.66 million, a net loss of CNY 97.86 million, and basic loss per share of CNY 0.18.
See our latest analysis for CARsgen Therapeutics Holdings.
The earnings update appears to have coincided with a sharp shift in sentiment, with a 42.97% 7 day share price return and a 17.85% 30 day share price return at HK$16.37. Meanwhile, the 1 year total shareholder return of 14.16% and...